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ABSTRACT 
Objective: To study the pharmacokinetics of ofloxacin using salivary drug concentration when 
administered alone or in combination with rifampicin (R), isoniazid (H) and pyrazinamide (Z) and 
also to assess the saliva to plasma concentration ratio. 
Material and Methods: Twelve healthy male volunteers were investigated on four different occa- 
sions with an interval of at least one week between occasions. They were administered ofloxacin, 
either alone or in combination with R, H and Z. A partially balanced incomplete block design was 
adopted and the subjects were randomly allocated to each group. Salivary and plasma concentra- 
tions of ofloxacin were measured at 1, 2, 3, 6 and 8 h after drug(s) administration using validated 
methods. 
Results: There were no significant differences between various pharmacokinetic parameters when 
ofloxacin was administered alone or in combination with R, H and Z. The mean saliva to plasma 
ratio of ofloxacin concentration was around 0.6. The bioavailability indices of ofloxacin in the 
saliva and plasma were similar in all the groups. 
Conclusion: Several pharmacokinetic parameters could be calculated using salivary concentra- 
tions of ofloxacin. The determination of ofloxacin levels in saliva may be useful in therapeutic 
drug monitoring and pharmacokinetic studies. 
KEY WORDS: Anti-TB drugs, ofloxacin, pharmacokinetics, saliva. 
Introduction 
Ofloxacin is a fluorinated carboxy quinolone exhibiting a 
marked bactericidal effect by inhibiting DNA gyrase.1,2 In Vitro 
studies on bactericidal activity against Mycobacterium tuber- 
culosis have suggested that ofloxacin is likely to be the most 
useful drug in the early stages of treatment and in preventing 
the emergence of resistance to other drugs.3 Its favorable 
pharmacokinetic features include good oral absorption and 
lack of metabolism resulting in less drug  interactions.4 
The determination of drug concentrations in the saliva has 
gained widespread acceptance in a variety of  settings.5 The 
estimation of drugs in the saliva has been employed for thera- 
peutic drug monitoring and for calculation of pharmacokinetic 
variables.6 The rational use of such determinations can pro- 
vide knowledge of patient-specific pharmacokinetic parameters 
leading to improved therapy.7 
Saliva can serve as an alternative body fluid for 
pharmacokinetic investigations. It can be collected with mini- 
mal patient discomfort and can be easily obtained on multiple 
occasions. It is particularly suitable for investigations in geri- 
atrics and pediatrics. Pharmacokinetic studies have shown that 
ofloxacin penetrates into saliva and its concentration corre- 
lates well with serum levels.8 However, the data available in 
the published studies are inconsistent and results reported 
for the ratio of saliva to serum concentrations show wide vari- 
ations. 
The present study was undertaken to evaluate the phar- 
macokinetics of ofloxacin in saliva when administered alone 
or in combination with other antituberculosis (TB) drugs, Viz. 
rifampicin (R), isoniazid (H) and pyrazinamide (Z) and to study 
the ratio of the saliva to plasma concentration by measuring 
ofloxacin concentrations in simultaneous saliva and plasma 
samples in healthy volunteers. 
Material and Methods 
Study participants 
Twelve healthy male volunteers with a mean age of 23 years 
(range 19-27 years) and a mean body weight of 56 kg (range 
45-69 kg) participated in the study. The volunteers were as- 
sessed to be healthy on the basis of medical history, hepatic 
and renal function tests. None of the subjects was taking any 
medication one week before or during the study for any ail- 
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ment and were non-alcoholics. The study protocol was ap- 
proved by the Institutional Ethics Committee and written in- 
formed consent was obtained from all the volunteers. 
Assay for the stated contents of the drugs 
Before starting the study, six tablets of ofloxacin (Dec- 
Pharma Ltd.), R (Asojsofcaps Pvt. Ltd.), H (Pfizer) and Z (Lu- 
pin Laboratories) were assayed on five different occasions to 
check for the quantity and the stated contents. The drugs em- 
ployed in the study were drawn from the same batch. 
Study design 
The volunteers were investigated on four different occa- 
sions with an interval of at least one week between occasions. 
They were administered ofloxacin on one occasion and 
ofloxacin in combination with R, H and Z on other occasions, 
as shown in Table 1. A partially balanced incomplete block 
design was adopted. Thus, the volunteers received either 
ofloxacin alone or in combination with R, H, Z and RHZ. After 
an overnight fast, the drugs were administered on an empty 
stomach after emptying the bladder. The dosages of the drugs 
administered to the volunteers were approximately 10 mg/kg 
body weight for R, 35 mg/kg for Z and the dosages of ofloxacin 
and H were 10 mg/kg for subjects weighing < 40 kg and 15 
mg/kg for subjects weighing > 40 kg. 
Sample collection 
On each occasion, 2-3 ml of paired samples of saliva and 
heparinized blood were collected at 1, 2, 3, 6 and 8 h after 
oral administration of the drug(s). Plasma was separated and 
stored. The study participants were instructed to wash their 
oral cavity and a piece of unsweetened, unflavored chewing 
gum was used to stimulate salivary secretion. The saliva sam- 
ples were frozen at -20°. They were thawed the following 
day, centrifuged and the supernatant was separated. The sa- 
liva and plasma samples were stored at -20°C. By storing bio- 
Table 1 
Ofloxacin administered alone and in combination to healthy 
volunteers 
Volunteer no. Occasions 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
1 2 
0 OH 
OH OZ 
OR 0 
ORHZ OZ 
OZ OH 
ORHZ O 
O OR 
OR OZ 
OZ O 
OR O 
O ORHZ 
O 
3 4 
OZ OR 
O ORHZ 
OH OZ 
O OH 
O OR 
OZ 
OZ 
O 
O: Ofloxacin, R: Rifampicin, H: Isoniazid, Z: Pyrazinamide 
The number of volunteers in each group: O=12, OR=6, OH-5 OZ=9,ORHZ=4 
logical samples under these conditions, no detectable drug 
decomposition takes place. 
Assay of ofloxacin 
Ofloxacin concentrations in saliva and plasma were deter- 
mined by the plate diffusion method employing a strain of E.coli 
as described elsewhere.9 In brief, the organism seeded in the 
autoclaved nutrient agar was poured into sterile petriplates. Wells 
of 2 mm diameter were cut. Ofloxacin standards ranging from 
0.25-8.0 mg/ml in pooled saliva and plasma and the drug in sa- 
tiva and plasma samples were set up in quadruplicate. The con- 
centrations of the drug were obtained from the regression line of 
the zone of inhibition on log concentrations of the standards. 
The assays were undertaken after coding the samples. 
Pharmacokinetic analysis 
Peak ofloxacin concentration (Cmax) in saliva and plasma 
as well as the time at which peak concentration was attained 
(tmax) were obtained from the measured data. The elimination 
rate constant (Kel) was calculated from the terminal log-lin- 
ear decline of concentrations in the measured fluid. Terminal 
elimination half-life (t1/2) was calculated as 0.693/Kel. The ar- 
eas under the concentration-time curve (AUC) (0-8 h) for 0 
were calculated by the trapezoidal rule. Bioavailability of 0 
for each drug combination was expressed as an index (B.I.) 
and calculated as the ratio of drug combination to that of 0 
alone (control). 
Data analysis was performed using SPSS (version 10.5) 
package. Differences among the treatment groups were de- 
termined using one-way ANOVA. P values <0.05 were consid- 
ered significant. 
Results 
Based on the salivary concentrations of ofloxacin at differ- 
ent time points, several pharmacokinetic variables were cal- 
culated (Table 2). The mean Cmax values of ofloxacin when ad- 
ministered alone and in combination with R, H, Z and RHZ 
were 4.88,5.38,4.36,4.63 and 5.18 mg/ml respectively. There 
were no significant differences in the Cmax and the tmax of 
ofloxacin between the different groups. 
The concentrations of ofloxacin in saliva were much lower 
than those in plasma. The C,, values of ofloxacin in plasma 
when administered alone and in combination with R, H, Z and 
RHZ were 7.14, 6.98, 7.19, 6.06 and 6.38 mg/ml respectively. 
The mean saliva to plasma ratio of ofloxacin concentrations 
was calculated at all time points and it was around 0.6. The 
correlation coefficient between plasma and saliva concentra- 
tion of ofloxacin was 0.94. The mean saliva to plasma (S/P) 
ratio of ofloxacin concentration when given alone and in com- 
bination was compared (Table 2). There was no significant dif- 
ference between the groups. The bioavailability indices of 
ofloxacin in saliva and plasma calculated on the basis of C, 
and AUC (in comparison with various combinations) are shown 
in Table 3. They are similar in all the groups. 
Discussion 
Ofloxacin has proved to be a particularly valuable addition 
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Table 2 
Pharmacokinetic parameters of ofloxacin in saliva when administered alone and in combination 
Parameter O (n=12) OR (n=6) OH (n=5) OZ (n=9) ORHZ (n=4) 
Cmax µg/ml 4.80 ± 1.51 5.38 ± 1.26 4.36 ± 1.65 4.63 ± 1.05 5.18 ±2.42 
tmaxh 1.33 ± 0.65 1.50 ± 0.55 2.00 ± 0.71 1.78 ± 0.67 1.50± 1 .00 
t1/2 h 4.23 ± 0.76 4.84 ± 1.49 4.26 ± 0.81 3.07 ± 0.47 7.54 ± 5.22 
17.34 ± 3.98 AUC µg/rnl.h (0-8 h) 15.59 ± 5.41 18.94 ± 2.80 13.49 ± 4.83 15.77 ± 4.37 
Saliva/plasrna ratio 0.6 ± 0.1 0.6 ± 0.1 0.5 ± 0.1 0.6 0.1 0.6 ± 0.1 
Values are mean ± SD. O: Ofloxacin, R: Rifampicin, H: Isoniazid, Z: Pyrazinamide 
Table 3 
Bioavailability indices of ofloxacin in saliva and plasma 
Bioavaiiability index 
Group Cmax AUC 
Plasma Saliva Saliva Plasma 
O Vs OR 1.1 1 .0 1.2 1.2 
0 Vs OH 0.9 1 .0 0.9 1 .1 
0 Vs OZ 1 ..0 0.9 1 .0 1 .0 
0 Vs ORHZ 1.1 0.9 1.1 1 .0 
to the available anti-TB drugs with a MIC of 1.0 mg/ml against 
Mycobacterium tuberculosis. The effectiveness of ofloxacin 
against Mycobacterium tuberculosis was studied by Crowle et 
al10 and their results reveal its clinical usefulness. 
Using saliva instead of blood for pharmacokinetic investi- 
gations has obvious practical advantages. It is a painless, non- 
invasive procedure, hence suitable for the collection of multi- 
ple specimens. Variable results have been reported for the ratio 
of saliva to serum concentrations. Koizumi et al11 reported a 
ratio of 1.0 between 2-8 h after administration of a 300 mg 
dose. Fujita et al12 in their studies on patients with renal im- 
pairment had reported a ratio of 1 : 1 for saliva to serum con- 
centrations. However, Warlich et al,13 have reported a ratio of 
0.6 and a close relation of levels in the saliva and serum (r= 
0.99), which is consistent with our findings. The mean S/P 
ratio of ofloxacin was around 0.6 and this remained the same 
when ofloxacin was given in any combination. The S/P ratio is 
a possible measure of the amount of protein binding to the 
drug. There was a good correlation (0.94) with respect to drug 
concentrations. 
The present study shows that several pharmacokinetic 
parameters can be calculated using salivary concentrations 
of ofloxacin as can be done with plasma. The estimation of 
ofloxacin levels in saliva seems to be useful in therapeutic 
drug monitoring and pharmacokinetic studies. 
Based on the salivary levels, the present study compares 
the pharmacokinetic parameters of ofloxacin when given alone 
and in combination with other anti-TB drugs namely R, H and 
Z. The pharmacokinetic parameters such as Cmax, tmax, AUC, 
and t1/2 did not change when given in combination with other 
anti-TB drugs suggesting that the pharmacokinetics of ofloxacin 
do not get affected or altered when administered with the other 
anti-TB drugs. 
When ofloxacin was administered in combination with three 
other drugs, namely R, H and Z, there were variations in the 
pharmacokinetic parameters calculated based on the salivary 
estimates. This could be due to the small sample size in this 
group (n=4) and interindividual differences in the absorption 
and metabolism of the drug. 
The microbiological assay (MBA) employed for the estima- 
tion of ofloxacin in the saliva and plasma is very simple, spe- 
cific, sensitive and reproducible, and does not require sophis- 
ticated equipment. This method was evaluated in samples 
wherein drug levels were also measured by HPLC according 
to the method of Immanuel et ali4 A very good correlation 
(0.99) was observed suggesting either method may be useful 
for pharmacokinetic studies. 
It can, therefore, be concluded that for bioavailability stud- 
ies, invasive blood collection can be replaced by simple non- 
invasive saliva collection. Further investigations are required 
to determine whether the concentration of ofloxacin in saliva 
can act as a valid index after multiple dosing. In this regard, a 
larger population sampling is required before any general state- 
ments regarding the utility of salivary measurements of 
ofloxacin can be made. 
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